鎮痙剤の世界市場 - 2022年～2029年

当レポートでは、世界の鎮痙剤市場について調査し、市場の概要とともに、タイプ別、用途別、投与経路別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 世界の鎮痙剤市場の調査手法と範囲

第2章 世界の鎮痙剤市場-市場の定義と概要

第3章 世界の鎮痙剤市場-エグゼクティブサマリー

• タイプ別市場内訳
• 用途別市場内訳
• 投与経路別市場内訳
• エンドユーザー別市場内訳
• 地域別の市場内訳

第4章 世界の鎮痙剤市場-市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 世界の鎮痙剤市場-業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制分析

第6章 世界の鎮痙剤市場-COVID-19分析

第7章 世界の鎮痙剤市場-タイプ別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、タイプ別
  • 市場魅力指数、タイプ別
• ジシクロベリン塩酸塩
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• ヒヨスチアミン
• ロペラミド塩酸塩

第8章 世界の鎮痙剤市場-用途別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、用途別
  • 市場魅力指数、用途別
• 過敏性腸症候群
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• 腹痛
• その他

第9章 世界の鎮痙剤市場-投与経路別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、投与経路別
  • 市場魅力指数、投与経路別
• 経口
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• 注射
• 舌下

第10章 世界の鎮痙剤市場-エンドユーザー別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、エンドユーザー別
  • 市場魅力指数、エンドユーザー別
• 病院
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• オンライン薬局
• 小売薬局
• その他

第11章 世界の鎮痙剤市場-地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）、地域別
  • 市場魅力指数、地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第12章 世界の鎮痙剤市場-競合情勢

• 主な発展と戦略
• 企業シェア分析
• 製品のベンチマーク
• 注目すべき主要企業

第13章 世界の鎮痙剤市場-企業プロファイル

• Allergan
• Hikma Pharmaceuticals
• Lannett
• Mylan
• Novartis AG
• Pfizer Inc
• Aurobindo Pharma
• Sanofi
• Teva Pharmaceuticals
• Astellas Pharmaceuticals Inc

第14章 世界の鎮痙剤市場-DataM

Market Overview

The global antispasmodics drug market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Antispasmodics are a medicine that can help control some symptoms caused by the gut (intestines), specifically gut spasms. Antispasmodic medications treat symptoms like stomach pain and cramping (spasm). They are most commonly used to treat irritable bowel syndrome symptoms.

Market Dynamics

The global antispasmodics drugs market is driven by factors such as the high prevalence of irritable bowel syndrome and the adoption of a sedentary lifestyle. Furthermore, high patient awareness and treatment advancements are influencing factors driving the market growth. Increasing research and development and increasing funding and investment in the field of life science research will drive the market growth

The pharmaceutical industry's expansion is expected to propel the antispasmodics medicines market forward in the upcoming years. An increase in the prevalence of irritable bowel syndrome is expected to help the antispasmodics medications industry in the coming years. In addition, the increasing rate of investment in the antispasmodics medication market is predicted to boost growth prospects soon. In 2019, the pharmaceutical sector spent $83 billion on research and development. These costs were used to fund several operations, including the discovery and testing of novel medications, the development of incremental advancements such as product expansions, and clinical testing for safety and marketing considerations. After adjusting for inflation, that sum is around ten times the industry spent in the 1980s.

The quality of medications and their use has increased throughout time due to the growing number of medical research projects. This has benefited in comprehending the benefits of various medications in the treatment of various chronic conditions. Furthermore, the market expansion is expected to increase research and development.

Furthermore, the number of adults and the elderly population is growing, which means that the challenges that older people confront are also growing. This has resulted in the use of medications that aid in treating a variety of ailments. As a result, the market for antispasmodics medications is expected to expand. The proportion of the world's population aged 60 and up will nearly double from 12 percent to 22 percent between 2015 and 2050.By 2023, the number of persons aged 60 and more will outweigh youngsters under five.By 2050, 80% of the world's elderly will live in low- and middle-income countries.The population is aging at a considerably higher rate than in the past.(Source :World Health Organization)

Furthermore, the area of medicine is evolving, and new drugs are being produced to speed up the treatment process better and improve the quality of the therapy so that side effects are reduced. Rapid medical research and development and a better understanding of pharmacological characteristics and their usage in treating chronic diseases are expected to drive market growth. These advances will aid the market's future growth by creating better pharmaceuticals to treat life-threatening disorders. These factors, as mentioned above, have a significant impact on the overall antispasmodics drug market.

Side effects caused by antispasmodics drugs is likely to hamper the market growth

Dizziness, drowsiness, weakness, blurred vision, dry eyes, dry mouth, nausea, constipation, and abdominal bloating are all side effects of antispasmodics medications. Any drug's use is restricted because the government establishes guidelines to monitor how and where the medications are utilized. This is expected to influence the market for anticholinergic medications negatively. Furthermore, these medicines have negative effects that may cause them to be used less frequently. To overcome these limitations, the market must continue to develop and upgrade.

COVID-19 Impact Analysis

During the COVID-19 pandemic, the antispasmodics drugs market had shrunk significantly. The pandemic has made it tougher to bring new medications to market in the hopes of earning market share or reaching sales projections. Aside from new diagnoses and regimen switching, marketing channels aren't as strong as before the epidemic. The few open channels continue to be dominated by COVID-19 programming. COVID-19 has slowed down clinical trials across the board, notably those in the early stages of development. As traditional study sites closed, researchers were often unable to collect data remotely, and many patients became less willing to participate. Some therapeutic fields were particularly heavily damaged. While some development time can be made up, there are concerns about resource allocation and digital technology expenditures to keep trials running now and in the future.

Segment Analysis

The irritable bowel syndrome segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Irritable bowel syndrome(IBS) is a collection of symptoms that affect your digestive system. It is a common but unpleasant gastrointestinal disorder. Irritable bowel syndrome patients experience excessive gas, abdominal pain, and cramping. The highest rates of irritable bowel syndrome are assumed to be in developed countries, while the lowest are in developing regions; colder climate regions and urban areas have a higher rate of irritable bowel syndrome than warmer climate regions and rural areas. Internationally, the incidence of irritable bowel syndrome ranges from 0.5-24.5 cases for ulcerative colitis to 0.1-16 cases per 100,000 person-years for Crohn's disease. Irritable bowel syndrome has a prevalence of 396 cases per 100,000 people in the United States each year. In the United States, in 2020, there will be approximately 2.5 million people suffering from inflammatory bowel disease. The prevalence of irritable bowel disease in the US population is expected to rise to around 3.5 million by 2030.(Source:World Health Organization).

Antispasmodics drugs like Alverine citrate, in combination with simethicone, effectively reduced abdominal pain and discomfort; while otilonium bromide also improved defecation problems. An increasing number of populations facing these irritable bowel syndrome is a major factor contributing to the significant growth of the segment in the forecast period.

Geographical Analysis

North America region holds the largest market share of global antispasmodics drug market

The North American antispasmodics drugs market is expected to have a considerable market share because of its well-established healthcare infrastructure and the growing number of organized healthcare systems. Some of the factors propelling the market in these regions are the rising prevalence of gastrointestinal problems and increased government measures that look toward shorter periods of patent exclusivity for new medication applications. Furthermore, the industry is being driven by a huge population, rising disposable income, and increased patient awareness, to name a few aspects.

The Asia-Pacific economy is expanding rapidly. India, China, Japan, and Australia are propelling the region's economic development. The main source of concern in this region is the provision of adequate healthcare for the region's rapidly rising population. With the opening of new hospitals and pharmacies in this area. Medication research, development, production, and distribution are all handled by the pharmaceutical business. Pharmaceutical industries revenues worldwide were 1.27 trillion US dollars in 2020, indicating that the market has grown significantly over the last two decades. Additionally, rising healthcare spending and increased government initiatives are two aspects supporting the industry.

Competitive Landscape

The global market for antispasmodics drugs is moderately competitive, with several major players. Allergan, Hikma Pharmaceuticals, Lannett, Mylan, Novartis AG, Pfizer Inc, Aurobindo Pharma, Sanofi , Teva Pharmaceuticals and Astellas Pharma Inc are among the market's major players. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antispasmodics drug market globally. For instance, in May 27 2020, The FDA approves VESIcare LSTM (solifenacin succinate) Oral Suspension for Pediatric Patients.

Allergan Plc

Overview:

Allergan Ltd (Allergan), an AbbVie Inc subsidiary, is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilars, and over-the-counter (OTC) pharmaceutical products. It provides products in the following categories: eye care, medical aesthetics, dermatology, central nervous system, gastroenterology, women's health, urology, and anti-infective therapeutics. The company's products are sold to retailers, drug wholesalers, and distributors, including national retail drug and food store chains, mail order retailers, hospitals, clinics, government agencies, and managed healthcare providers such as health maintenance organizations and other institutions. It is present in the Americas, Europe, Asia-Pacific, the Middle East, and Africa. The company's headquarters are in Dublin, Ireland.

Product Portfolio:

Bentyl: Dicyclomine(Bentyl) is used to treat irritable bowel syndrome, an intestinal problem. It aids in the relief of stomach and intestinal cramping symptoms. This medication works by slowing the gut's natural movements and relaxing the muscles in the stomach and intestines. Dicyclomine belongs to the anticholinergic/antispasmodic drug class.

Why Purchase the Report?

Visualize the composition of the global antispasmodics drug market segmentation by drug type, application, route of administration, end-user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in global antispasmodics drug market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global antispasmodics drug market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global antispasmodics drug market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Global Antispasmodics Drug Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Antispasmodics Drug Market- Market Definition and Overview

3. Global Antispasmodics Drug Market- Executive Summary

• 3.1. Market Snippet by Product
• 3.2. Market snippet by Application
• 3.3. Market snippet by Route of Administration
• 3.4. Market Snippet by End-User
• 3.5. Market Snippet by Region

4. Global Antispasmodics Drug Market- Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. High prevalence of irritable bowel syndrome.
    • 4.1.1.2. Adoption of sedentary lifestyle.
    • 4.1.1.3. High patient awareness level and improvement in treatment.
    • 4.1.1.4. Increasing investments and funding in the field of life science research.
  • 4.1.2. Restraints:
    • 4.1.2.1. Side effects of antispasmodics drugs
    • 4.1.2.2. Stringent regulations.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Global Antispasmodics Drug Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. Global Antispasmodics Drug Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Global Antispasmodics Drug Market- By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
  • 7.1.2. Market Attractiveness Index, By Drug Type Segment
• 7.2. Dicyclomine hydrochloride *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Hyoscyamine
• 7.4. Loperamide hydrochloride

8. Global Antispasmodics Drug Market- By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Irritable Bowel Syndrome*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Stomach Cramps
• 8.4. Others

9. Global Antispasmodics Drug Market- By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Oral*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Injectable
• 9.4. Sublingual

10. Global Antispasmodics Drug Market- By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User Segment
• 10.2. Hospital *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 10.3. Online Pharmacy
• 10.4. Retail Pharmacy
• 10.5. Others

11. Global Antispasmodics Drug Market- By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

12. Global Antispasmodics Drug Market- Competitive Landscape

• 12.1. Key Developments and Strategies
• 12.2. Company Share Analysis
• 12.3. Product Benchmarking
• 12.4. Key Companies to Watch

13. Global Antispasmodics Drug Market- Company Profiles

• 13.1. Allergan *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. Hikma Pharmaceuticals
• 13.3. Lannett
• 13.4. Mylan
• 13.5. Novartis AG
• 13.6. Pfizer Inc
• 13.7. Aurobindo Pharma
• 13.8. Sanofi
• 13.9. Teva Pharmaceuticals
• 13.10. Astellas Pharmaceuticals Inc

LIST NOT EXHAUSTIVE

14. Global Antispasmodics Drug Market- DataM

• 14.1. Appendix
• 14.2. About Us and Services
• 14.3. Contact Us